Comparison of Inflammatory Markers and Incidence of Comorbidities in Patients on Antiretroviral Therapy With Second-generation Anti-integrase Drugs on Triple Versus Dual Therapy
Comparison of Inflammatory Markers and Incidence of Comorbidities in Patients on Antiretroviral Therapy (ART) With Second-generation Anti-integrase Drugs on Triple Versus Dual Therapy
Centre Hospitalier Universitaire de Nice
500 participants
Feb 16, 2023
INTERVENTIONAL
Conditions
Summary
HIV-infected patients develop comorbidities earlier than the general population. Immune activation with the secretion of pro-inflammatory cytokines would play a major role in the occurrence of these comorbidities. Numerous factors, called risk factors, already identified in the general population and confirmed in patients with HIV virus favor the occurrence of these comorbidities but cannot alone explain the overrepresentation and precocity of these comorbidities in the HIV population. Investigators hypothesize that optimization or simplification with certain classes of antiretrovirals modify the inflammatory response and are predictive factors for the occurrence of comorbidities
Eligibility
Inclusion Criteria10
- HIV-1 infection
- Age \> 40 years or adults with more than 10 years of antiretroviral therapy
- Switching to BIC/FTC/TAF or DTG/3TC or DTG+3TC within the last 2 years
- Plasma HIV-1 RNA viral load \< 50 copies/ml for more than 6 months
- Absence of chronic hepatitis B infection
- Absence of genotype mutations on Dolutegravir (DTG) or Bictegravir (BIC) or tenofovir alafenamide TAF
- Daily use of antiretroviral therapy
- Effective contraception for women of childbearing potential will be requested
- Signed informed consent
- Enrollment in a Social Security plan
Exclusion Criteria8
- Non-daily or intermittent antiretroviral therapy regimen (e.g., 4 or 5 days a week)
- Pregnancy or breastfeeding
- Vulnerable persons according to article L.1121-6 of the public health code Persons unable to give consent according to article L.1121-8 of the public health code
- Opportunistic infections during curative treatment
- HIV-2 infection
- Active hepatitis C
- Refusal to participate
- Withdrawal of informed consent by the patient
Interventions
Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)
Evolution of CD4/CD8 ratio
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05699785